These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29870792)

  • 1. Recommendations toward a human pathway-based approach to disease research.
    Marshall LJ; Austin CP; Casey W; Fitzpatrick SC; Willett C
    Drug Discov Today; 2018 Nov; 23(11):1824-1832. PubMed ID: 29870792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Affairs of the Heart: Innovation in Cardiovascular Research and Development.
    Honig P; Terzic A
    Clin Pharmacol Ther; 2017 Aug; 102(2):162-168. PubMed ID: 28718903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
    Bax R; Green S
    J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges of biomarkers in drug discovery and development.
    Goodsaid F
    Expert Opin Drug Discov; 2012 Jun; 7(6):457-61. PubMed ID: 22471322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2014 Jun; 30(5):371-2. PubMed ID: 24897062
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 7. New players join the drug development game.
    Lott R
    Health Aff (Millwood); 2014 Oct; 33(10):1711-3. PubMed ID: 25288413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New paradigm for drug developments--from emerging market statistical perspective.
    Quan H; Chen X; Zhang J; Zhao PL
    Contemp Clin Trials; 2013 Nov; 36(2):697-703. PubMed ID: 23810938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan.
    Yamanaka T; Kano S
    Expert Opin Ther Pat; 2016; 26(4):497-503. PubMed ID: 26881292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy crisis in the spotlight--is open collaboration between academia and industry the answer?
    Kaski JC
    Cardiovasc Drugs Ther; 2011 Apr; 25(2):187-8. PubMed ID: 21503624
    [No Abstract]   [Full Text] [Related]  

  • 11. How can attrition rates be reduced in cancer drug discovery?
    Moreno L; Pearson AD
    Expert Opin Drug Discov; 2013 Apr; 8(4):363-8. PubMed ID: 23373702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process.
    Liberti L; Breckenridge A; Eichler HG; Peterson R; McAuslane N; Walker S
    Clin Pharmacol Ther; 2010 Jan; 87(1):27-31. PubMed ID: 20019699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.
    Jones HM; Chen Y; Gibson C; Heimbach T; Parrott N; Peters SA; Snoeys J; Upreti VV; Zheng M; Hall SD
    Clin Pharmacol Ther; 2015 Mar; 97(3):247-62. PubMed ID: 25670209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 16. Improving clinical trial sampling for future research - an international approach: outcomes and next steps from the DIA future use sampling workshop 2011.
    Warner AW; Bienfait KL; Bledsoe M; Burckart G; Flamion B; Knoppers B; Nelsen AJ; Rudman A; Sieffert NJ; Uyama Y
    Pharmacogenomics; 2013 Jan; 14(1):103-12. PubMed ID: 23252952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis to guide orphan drug development.
    Lesko LJ
    Clin Pharmacol Ther; 2012 Aug; 92(2):258-61. PubMed ID: 22739138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Industry and regulatory performance in 2012: a year in review.
    Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
    Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.
    Jackson N; Atar D; Borentain M; Breithardt G; van Eickels M; Endres M; Fraass U; Friede T; Hannachi H; Janmohamed S; Kreuzer J; Landray M; Lautsch D; Le Floch C; Mol P; Naci H; Samani NJ; Svensson A; Thorstensen C; Tijssen J; Vandzhura V; Zalewski A; Kirchhof P
    Eur Heart J; 2016 Mar; 37(9):747-54. PubMed ID: 26077039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining Manufacturing Readiness for Breakthrough Drug Development.
    Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
    AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.